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Effectiveness of seasonal malaria chemoprevention at scale 
in west and central Africa: an observational study
ACCESS-SMC Partnership*
Summary
Background Seasonal malaria chemoprevention (SMC) aims to prevent malaria in children during the high malaria 
transmission season. The Achieving Catalytic Expansion of SMC in the Sahel (ACCESS-SMC) project sought to 
remove barriers to the scale-up of SMC in seven countries in 2015 and 2016. We evaluated the project, including 
coverage, effectiveness of the intervention, safety, feasibility, drug resistance, and cost-effectiveness.
Methods For this observational study, we collected data on the delivery, effectiveness, safety, influence on drug 
resistance, costs of delivery, impact on malaria incidence and mortality, and cost-effectiveness of SMC, during its 
administration for 4 months each year (2015 and 2016) to children younger than 5 years, in Burkina Faso, Chad, 
The Gambia, Guinea, Mali, Niger, and Nigeria. SMC was administered monthly by community health workers who 
visited door-to-door. Drug administration was monitored via tally sheets and via household cluster-sample coverage 
surveys. Pharmacovigilance was based on targeted spontaneous reporting and monitoring systems were 
strengthened. Molecular markers of resistance to sulfadoxine–pyrimethamine and amodiaquine in the general 
population before and 2 years after SMC introduction was assessed from community surveys. Effectiveness of 
monthly SMC treatments was measured in case-control studies that compared receipt of SMC between patients with 
confirmed malaria and neighbourhood-matched community controls eligible to receive SMC. Impact on incidence 
and mortality was assessed from confirmed outpatient cases, hospital admissions, and deaths associated with 
malaria, as reported in national health management information systems in Burkina Faso and The Gambia, and 
from data from selected outpatient facilities (all countries). Provider costs of SMC were estimated from financial 
costs, costs of health-care staff time, and volunteer opportunity costs, and cost-effectiveness ratios were calculated as 
the total cost of SMC in each country divided by the predicted number of cases averted.
Findings 12 467 933 monthly SMC treatments were administered in 2015 to a target population of 3 650 455 children, 
and 25 117 480 were administered in 2016 to a target population of 7 551 491. In 2015, among eligible children, mean 
coverage per month was 76·4% (95% CI 74·0–78·8), and 54·5% children (95% CI 50·4–58·7) received all 
four treatments. Similar coverage was achieved in 2016 (74·8% [72·2–77·3] treated per month and 53·0% [48·5–57·4] 
treated four times). In 779 individual case safety reports over 2015–16, 36 serious adverse drug reactions were reported 
(one child with rash, two with fever, 31 with gastrointestinal disorders, one with extrapyramidal syndrome, and one 
with Quincke’s oedema). No cases of severe skin reactions (Stevens-Johnson or Lyell syndrome) were reported. SMC 
treatment was associated with a protective effectiveness of 88·2% (95% CI 78·7–93·4) over 28 days in case-control 
studies (2185 cases of confirmed malaria and 4370 controls). In Burkina Faso and The Gambia, implementation of 
SMC was associated with reductions in the number of malaria deaths in hospital during the high transmission 
period, of 42·4% (95% CI 5·9 to 64·7) in Burkina Faso and 56·6% (28·9 to 73·5) in The Gambia. Over 2015–16, the 
estimated reduction in confirmed malaria cases at outpatient clinics during the high transmission period in the seven 
countries ranged from 25·5% (95% CI 6·1 to 40·9) in Nigeria to 55·2% (42·0 to 65·3) in The Gambia. Molecular 
markers of resistance occurred at low frequencies. In individuals aged 10–30 years without SMC, the combined 
mutations associated with resistance to amodiaquine (pfcrt CVIET haplotype and pfmdr1 mutations [86Tyr and 
184Tyr]) had a prevalence of 0·7% (95% CI 0·4–1·2) in 2016 and 0·4% (0·1–0·8) in 2018 (prevalence ratio 0·5 [95% CI 
0·2–1·2]), and the quintuple mutation associated with resistance to sulfadoxine–pyrimethamine (triple mutation in 
pfdhfr and pfdhps mutations [437Gly and 540Glu]) had a prevalence of 0·2% (0·1–0·5) in 2016 and 1·0% (0·6–1·6) 
in 2018 (prevalence ratio 4·8 [1·7–13·7]). The weighted average economic cost of administering four monthly SMC 
treatments was US$3·63 per child.
Interpretation SMC at scale was effective in preventing morbidity and mortality from malaria. Serious adverse 
reactions were rarely reported. Coverage varied, with some areas consistently achieving high levels via door-
to-door campaigns. Markers of resistance to sulfadoxine–pyrimethamine and amodiaquine remained uncommon, 
but with some selection for resistance to sulfadoxine–pyrimethamine, and the situation needs to be carefully 
monitored. These findings should support efforts to ensure high levels of SMC coverage in west and central 
Africa.
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Introduction
In the sub-Sahel region, from southern Senegal and 
northern Guinea to Chad and northern Cameroon, most 
malaria morbidity and mortality occurs during and 
immediately after a short rainy season. Seasonal malaria 
chemoprevention (SMC), whereby antimalarial sulfa-
doxine–pyrimethamine plus amodi aquine (SP + AQ) are 
administered once a month to prevent malaria,1–9 has 
been welcomed as a new tool, offering a high degree of 
personal protection at moderate cost. Following endorse-
ment of SMC by WHO in 2012,10–12 countries have been 
quick to include SMC in their strategic plans for malaria 
control. Small-scale pilot schemes showed preliminary 
evidence of effectiveness13–15 and by 2014, eight countries 
had SMC programmes, reaching about 2·5 million 
children (appendix p 2), but insufficient funding and poor 
supplies of quality-assured drugs for SMC hindered 
further scale-up. The Unitaid-funded project, Achieving 
Catalytic Expansion of SMC in the Sahel (ACCESS-SMC), 
sought to remove barriers to scale-up. ACCESS-SMC 
implemented SMC on a large scale in seven countries, 
to create demand and influence the market for SMC 
drugs in terms of manufacturing capacity and prices, and 
to evaluate effectiveness of the intervention to address 
concerns about safety, feasibility, and drug resistance. 
SMC was delivered to a target population of about 
3·6 million children (aged 3–59 months) in Burkina Faso, 
Chad, The Gambia, Guinea, Mali, Niger, and Nigeria 
in 2015, and about 7·6 million children in 2016 (appendix 
pp 3–4). From 2017, SMC delivery was continued by 
national programmes in all seven countries, and 
ACCESS-SMC continued in parts of Burkina Faso, 
Chad, and Nigeria not covered by national programmes. 
The project aimed to evaluate the safety and effective-
ness of SMC at scale, the costs of delivery, cost-
effectiveness, and effects on drug resistance, during 2015 




The present observational study collected data on the 
delivery, effectiveness and safety of monthly treatments, 
influence on drug resis tance, costs of delivery, impact 
on malaria incidence and mortality, and cost-effec-
tiveness of SMC, during its administration for 4 months 
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Research in context
Evidence before this study
We searched for publications with the search terms “seasonal 
malaria chemoprevention” (published since Jan 1, 2012) or “IPTc” 
or “intermittent preventive treatment in children” (published 
before Jan 1, 2012). Clinical trials done between 2002 and 2009 
showed that intermittent preventive treatment for malaria in 
children younger than 5 years during the transmission season 
substantially reduced the incidence of malaria. An effectiveness 
study in Senegal of monthly seasonal malaria chemoprevention 
(SMC) with sulfadoxine–pyrimethamine plus amodiaquine over 
three years (2008–11) showed that SMC reduced the incidence of 
malaria by 60%, and hospital admissions for malaria by 45% 
during the transmission season. Following WHO policy 
recommendations for SMC in 2012, pilot schemes by Médecins 
Sans Frontières provided early evidence of effectiveness, and 
surveys have shown reductions in prevalence of infection and 
anaemia following implementation of SMC. Cost-effectiveness 
has also been studied in Ghana. However, questions remained 
about the feasibility of implementing SMC effectively on a large 
scale, the risk of serious adverse drug reactions, the ability of SMC 
to prevent deaths from malaria, and the effects of widespread 
use on selection for resistance. There were also substantial 
barriers to access due to shortages of quality-assured drugs, 
increased cost of drugs, and the absence of child-friendly 
formulations. By 2014, although many countries had included 
SMC in their strategic plans for malaria control, SMC was 
available for only about 10% of eligible children.
Added value of this study
The Achieving Catalytic Expansion of SMC in the Sahel 
(ACCESS-SMC) project was undertaken to improve the 
availability of SMC drugs and evaluate the effectiveness of 
SMC at scale.
This study showed that high, equitable coverage was achieved 
overall, but coverage varied, with some countries achieving 
better coverage than others. Each monthly treatment provided 
a high degree of protection for 4 weeks. Molecular monitoring 
showed that drug resistant infections are uncommon, but some 
selection for resistance to sulfadoxine–pyrimethamine occurred. 
Serious side-effects were rare. SMC cost US$3·63 per child per 
year, and was highly cost-effective. The number of malaria cases 
at outpatient clinics and the number of deaths from malaria in 
hospital were substantially reduced when SMC was introduced.
Implications of all the available evidence
Despite the complexity of delivery, SMC has proved highly 
effective. 13 countries now have SMC programmes, which 
reached about 22 million children in 2019. Drug resistance is a 
threat, and continued molecular monitoring is needed to 
provide early warning of loss of effectiveness, and 
pharmacovigilance needs to be strengthened. SMC does not 
provide complete protection and additional measures are still 
needed, but its impact could be increased by optimising delivery, 
and, in some areas, increasing the number of monthly cycles to 
ensure children are protected throughout the high-risk period.
See Online for appendix
For the ACCESS-SMC website 
see https://www.access-smc.org/
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each year to children younger than 5 years, in Burkina 
Faso, Chad, The Gambia, Guinea, Mali, Niger, and 
Nigeria in 2015 and 2016. Children eligible to receive 
SMC were those aged between 3 and 59 months at the 
time of the first monthly treatment of the year (eligible 
to receive four treatments), and in a particular month, 
those aged at least 3 months and younger than 5 years 
at the time of the first cycle. Additionally, eligible 
children were those who were not unwell, were not 
known to have allergies to SMC drugs, and had not 
taken amodiaquine, sulfadoxine–pyrimethamine, or 
sulfa-containing antibiotics, in the previous 4 weeks. 
SMC delivery was monitored by distribution teams and 
assessed independently by household surveys. The 
effectiveness of SMC treat ments in preventing malaria 
was measured with case-control studies. The effect of 
SMC introduction on the number of confirmed malaria 
cases at health facilities was assessed from cases 
reported in national health management information 
systems (HMIS) databases, and individual patient data 
collected from selected clinics, before and during 
SMC introduction. National pharmacovigilance was 
strength ened in all countries. In addition, in part of the 
implementation area in Nigeria, a cohort of children 
was monitored for illness symptoms. Large-scale sur-
veys were used to measure the frequency of molecular 
markers of resistance to SMC drugs before and after 
two years of SMC at scale. Costs of SMC delivery, and 
cost-effectiveness, were estimated in each country. The 
timing of the various substudies is shown in the 
appendix (p 2).
The protocol covering all substudies was approved by 
the research ethics committee of London School of 
Hygiene & Tropical Medicine (London, UK) and by ethics 
com mittees in each participating country. Signed consent 
was obtained from caregivers for participation in the 
surveys and case-control studies after explaining aims 
and procedures with a standard script.
Drugs
Infant and child co-blister packs of SP+AQ were manu-
factured by Guilin Pharmaceutical (Shanghai, China; 
1 tablet of sulfadoxine–pyrimethamine 500 mg–25 mg 
and 3 tablets of amodiaquine 150 mg for children aged 
12–59 months, and half-strength tablets for infants 
aged 3–11 months). In 2015, non-dispersible tablets 
were used. From Feb 7, 2016, dispersible tablets became 
available, and 80% of tablets used for SMC in 2016 were 
dispersible (unpublished data). Due to an international 
shortage of sulfadoxine in 2014, only half of the planned 
quantity of drugs could be procured for 2015, and 
implementation was therefore limited to half of the 
planned distribution areas in 2015, expanding to all 
planned areas in 2016 when manufacturing capacity 
had increased to meet demand. SMC implementation 
areas and estimates of populations reached are provided 
in figure 1.
SMC delivery and coverage
A cascade model was used to train community drug 
distributors (volunteer distributors or community 
health workers [CHWs], referred to jointly as CHWs in 
this Article) and health facility staff to administer SMC 
drugs safely and to recognise and report adverse 
reactions. The job-aids used to help recognise adverse 
drug reactions and the training manual for SMC 
delivery (in English) are included in the appendix 
(pp 38, 43). Social mobilisation, via local announce-
ments with criers, radio, and other local communication 
channels, explained the programme and notified 
communities, days in advance, of the dates of each 
monthly SMC campaign. SMC was delivered primarily 
door-to-door, supplemented by making treatment 
available at health facilities and at other fixed dis-
tribution points. CHWs administered sulfadoxine–
pyrimethamine and the first dose of amodiaquine, 
leaving the blister pack with the caregiver to administer 
the remaining two doses of amodiaquine on each of the 
next 2 days. Children who were unwell were referred 
for assessment at the nearest health facility and 
could then receive SMC if they did not have malaria. In 
Mali, SMC was distributed by mobile teams from a 
central location in each com munity. These teams 
were equipped with malaria rapid diagnostic tests, 
artemisinin combination treatment, and other basic 
medicines in addition to SMC drugs so that they could 
do a rapid diagnostic test on any children who were 
unwell and treat them appropriately without the need 
for referral. Delivery exclusively at fixed points was 
used in urban areas in Niger in 2015, but this approach 
was replaced by door-to-door delivery in 2016. CHWs 
Figure 1: SMC implementation areas
Areas where SMC was implemented in 2015 are shown in blue, via the ACCESS-SMC project (dark blue) and other 
implementers (light blue). These areas continued SMC in 2016. Green shading shows the additional areas where 
SMC started in 2016, via the ACCESS SMC project (dark green) and other implementers (light green). In 2015, 
SMC programmes in nine countries reached about 7 million children, 3 million of them via ACCESS-SMC, and 
in 2016, programmes in 12 countries reached about 15 million children, 7 million via ACCESS-SMC (appendix p 3).16 
SMC=seasonal malaria chemoprevention. ACCESS-SMC=Achieving Catalytic Expansion of SMC in the Sahel.
SMC in 2015 (ACCESS-SMC)
SMC in 2015 (other implementers)
Areas starting SMC in 2016 (ACCESS-SMC)
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working in pairs for 4–5 days each month treated about 
50 children per pair per day, recording treatments on 
record cards held by the caregiver, in a village register, 
and on a tally sheet held by the CHWs (or, in The 
Gambia only, a QR code on the child’s SMC card was 
scanned with a smartphone and the data uploaded to a 
database via the Evaluate platform. At the end of each 
monthly campaign, tally sheets or database records 
were collated at health facilities and the number of 
treatments administered reported to the coordinating 
office of each country.
To assess SMC coverage, household cluster-sample 
surveys were done in each country at the end of each 
malaria transmission season (appendix p 4). Details of 
the survey sampling design are given in the appendix 
(p 7). Dates of treatments were noted from the SMC 
card and caregivers were asked about monthly SMC 
treatments received, to determine the mean percentage 
of children who received SMC each month, and the 
percentages who received 0, 1, 2, 3, and 4 treatments, 
estimated with 95% CIs, using a survey-weighted ratio 
estimator in Stata (version 15). A questionnaire was used 
to ask caregivers about use of bednets, adherence to the 
daily SMC doses in the most recent month, awareness of 
SMC campaign dates in advance, knowledge about 
SMC, and ownership of household assets as a measure 
of wealth.
Treatment effectiveness
Effectiveness of SMC treatments (in terms of the 
percentage reduction in clinical malaria incidence in 
the 28 days and 29–42 days after administration of the 
first daily dose of SMC each month) was estimated 
in five countries during the 2015 (The Gambia and 
Mali) and 2016 (Burkina Faso, Chad, The Gambia, 
Mali, and Nigeria) trans mission seasons with case-
control studies. Cases were children aged 3–59 months 
presenting at health facilities with documented fever 
and microscopically confirmed asexual Plasmodium 
falciparum parasitaemia. The children were visited at 
home by fieldworkers where SMC record cards were 
inspected and caregivers asked about SMC treat ments, 
adherence, and potential confounding factors including 
bednet use, caregiver education, and socio-economic 
status. The same information was collected for controls 
(two for each case), who were children from the same 
neighbourhood who were eligible to have received 
SMC. Further details and analysis methods are given in 
the appendix (pp 11–12).
Safety monitoring
Pharmacovigilance was based on targeted spontaneous 
reporting17 at health facilities, with a focus on known 
severe reactions to SMC drugs: severe skin reactions, 
liver disease, extrapyramidal syndrome, anaphylactic 
shock, and severe vomiting. Information on signs and 
symptoms was developed and distributed, with reporting 
forms, to health facilities (appendix pp 10–11). To assess 
the frequency of adverse reactions that did not lead to 
a health worker visit or health facility visit, CHWs 
administering SMC in three wards in Nigeria (two wards 
where there were four cycles of SMC and one ward where 
there was three cycles of SMC) to a cohort of about 
10 000 children asked each caregiver about any illness 
symptoms in the child after administration of SP + AQ in 
the previous month using a symptom questionnaire. 
Individual case safety reports were entered into VigiFlow 
and submitted to VigiBase (WHO’s individual case safety 
report database system). A committee was convened 
by WHO to review reports of serious adverse events 
associated with SMC, to provide advice about safety 
monitoring for SMC, and to report their findings to the 
WHO Advisory Committee on the Safety of Medicines 
and Medicinal Products. Individual case safety reports 
associated with SMC for the years 2015 and 2016, 
extracted from Vigibase on April 18, 2017, and additional 
case reports received by project teams which had not 
been submitted to Vigibase, were analysed.
Drug resistance
The prevalence of molecular markers of resistance 
to sulfadoxine–pyrimethamine and amodiaquine was 
mea sured in one second-level administrative area 
(district or equivalent area) per country, in representative 
house hold cluster-sample surveys of the district popu-
lation in 2016 and 2018. Surveys were designed to have 
at least 90% power to detect an odds ratio for a change 
in marker prevalence over 2 years of 1·4. Districts were 
chosen that included a site used for routine moni-
toring efficacy of first-line antimalarials, and that were 
starting SMC in 2016, except for The Gambia where 
SMC had started in all eligible areas in 2014. The full 
survey design is provided in the appendix (pp 12–14). 
In 2016 and 2018, in each country per year, finger-
prick blood samples on filter paper were taken from 
about 2000 children younger than 5 years and 2000 indi-
viduals between age 10 and 30 years, and shipped to 
the London School of Hygiene & Tropical Medicine 
(Department of Infection Biology) where samples 
positive for P falciparum by PCR were resistance-typed. 
DNA was extracted with a robotic platform, P falciparum 
chloroquine resistance transporter (pfcrt) genotyping 
was done via real-time PCR with hydrolysis probes, and 
direct sequencing was used for P falciparum multidrug 
resistance 1 (pfmdr1), dihydrofolate reductase (pfdhfr), 
and dihydropteroate synthetase (pfdhps) markers. For 
resistance mutations, prevalence each year was esti-
mated with a ratio estimator, and the fold increase in 
prevalence and 95% CIs were estimated by survey 
Poisson regression in Stata software (version 15; 
appendix p 13). We primarily present mutation preva-
lence in the older age group (10–30 years), who had not 
received SMC and therefore reflected the trend in the 
circulating parasite population.
For VigiFlow see https://www.
who-umc.org/global-
pharmacovigilance/vigiflow/
For VigiBase see https://www.
who-umc.org/vigibase/vigibase/
For the Evaluate platform see 
https://www.crs.org/evaluate
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Impact on malaria rates
The reduction in the number of malaria outpatient cases, 
inpatient cases, and malaria deaths in hospital in children 
younger than 5 years associated with intro duction of 
SMC, according to cases reported in HMIS databases and 
individual patient data, was estimated with a difference-
in-differences approach (appendix pp 19–21). Individuals 
aged 5 years and older were the control age group, with 
data on the same age groups in areas that did not 
introduce SMC as additional controls. Poisson regression 
models were fitted to the data on numbers of cases before 
and during the interven tion period in Stata. This approach 
corrected for changes in testing rates and use of 
insecticide-treated bednets, which increased in some 
countries during the study period but changed similarly 
in both age groups, and for the effect of removal of patient 
charges in Burkina Faso from 2016 (appendix pp 11–13). 
The Gambia and Burkina Faso had established District 
Health Information System 2 (DHIS2) databases before 
SMC scale-up and these national data bases were used for 
analyses of the effect of SMC on the number of reported 
outpatient malaria cases, the number of reported severe 
(hospitalised) cases, and the number of deaths in district 
hospitals attributed to malaria. In the other five countries, 
data on confirmed outpatient cases were collected from 
outpatient clinics. In each country, facil ities were selected 
(~30 per country) that had used parasitological confir-
mation of malaria cases for at least one year before 
introduction of SMC; had retained clinic registers; 
and were in areas where SMC was to be delivered via 
ACCESS-SMC starting in 2015 or 2016, or would not have 
implemented SMC by 2016. Data from facilities that had 
complete data for both age groups each month for at 
least one year before and one year after introduction of 
SMC (n=73 across all seven countries) were retained for 
analysis.
Costs and cost-effectiveness
Provider costs of SMC (in 2016 US$) in each country were 
estimated by use of an ingredients-based approach 
(appendix pp 17–18).18 Costed ingredients comprised finan-
cial costs (from accounting records of implementing non-
governmental organisation partners and via interviews 
with their personnel), volunteer opportunity costs (calcu-
lated from the number of days spent on distribution and 
related activities during each monthly cycle, and the 
Burkina Faso Chad The Gambia Guinea Mali Niger Nigeria Overall
2015
Target population 707 317 268 956 88 748 253 252 875 330 596 355 860 497 3 650 455
Total treatments administered 2 721 731 1 061 417 308 830 805 131 2 752 912 1 668 015 3 149 897 12 467 933
Number surveyed who were eligible for 
four treatments
786 707 690 1258 740 4113 1082 9376




















































Reported adherent percentage to 3-day 


















Target population 2 056 169 514 042 90 925 438 123 1 492 137 1 050 932 1 909 163 7 551 491
Total treatments administered 5 780 062 2 511 371 297 453 1 750 224 4 667 224 3 810 088 6 301 058 25 117 480
Number surveyed who were eligible for 
four treatments
874 1010 1138 1743 799 5646 1853 13 063
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Target populations aged 3–59 months were estimated based on census projections.20 Mean coverage per month, the percentage of children who received SMC treatment at least once in the year, the percentage 
of children who received SMC four times, and reported adherence (percentage of those who received SMC in the month before the survey who received all three daily doses) were estimated for children who were 
eligible to receive four treatments of SMC. 95% CIs are shown in parentheses. Four monthly cycles of treatment were administered each year, except in 2016 in Nigeria, where the first cycle was not implemented 
in some wards due to delays in registration of dispersible tablets, and in three districts in Chad, where the fourth cycle was not implemented in 2016 due to a shortage of drugs. In addition to the number shown, 
a total of 1695 children aged 6–7 years were surveyed in 2015 and 2062 in 2016, of whom 53·0% (95% CI 48·7–57·3) in 2015 and 62·4% (55·7–69·1) in 2016 had received SMC at least once each year. 
SMC=seasonal malaria chemoprevention.
Table 1: Monthly treatments of sulfadoxine–pyrimethamine plus amodiaquine administered in 2015 and 2016, and estimates of SMC coverage from cluster-sample surveys
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national average minimum daily wage), and costs of 
government staff time (based on time spent supporting 
the campaign according to the average monthly gross 
income). Per diem payments were considered financial 
costs. Start-up costs (such as those for the development of 
training materials and reporting tools) were excluded. The 
weighted average cost of four treatments per child was 
obtained by dividing the total recurrent cost by the total 
number of doses administered divided by 4. The case 
numbers of malaria, severe malaria, and malaria deaths 
that should have been averted by SMC were calculated 
from the number of SMC treatments administered, 
estimates of incidence rates without SMC derived from the 
malaria model of Imperial College London,19 and case-
control estimates of the effectiveness of each monthly 
treatment (appendix p 34). Cost-effectiveness ratios were 
calculated by dividing the total cost of the SMC intervention 
in each country by the predicted number of cases averted. 
Potential cost savings from a provider perspective were 
calculated from the diagnostic and treatment costs for 
non-severe and severe malaria cases averted, and assumed 
60% of malaria cases were diagnosed and treated. All cost 
analyses were done in Microsoft Excel.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. All authors had full access to all the data in 
the study and accept responsibility for the decision to 
submit for publication.
Results
In 2015, a total of 12 467 933 treatments were admin-
istered over 4 monthly cycles to a target population 
of 3 650 455 children by 19 428 CHWs. In 2016, 
25 117 480 treatments were administered to a target popu-
lation of 7 551 491 children by 47 238 CHWs (table 1). 
Timings of the monthly cycles in 2015 are shown in the 
appendix (p 8). Four monthly cycles of treatment were 
administered each year, except in 2016 in Nigeria, where 
the first cycle was not implemented in some wards due 
to delays in registration of dispersible tablets, and in 
three districts in Chad, where the fourth cycle was not 
implemented in 2016 due to a shortage of drugs.
In 2015, 12 777 children were surveyed at the end of the 
transmission season; 9376 were eligible to receive 
four treatments, of whom 86·4% (95% CI 83·4–89·3) 
were treated at least once. The mean coverage per month 
was 76·4% (95% CI 74·0–78·8), and 54·5% children 
(95% CI 50·4–58·7) received all four treatments. In 2016, 
15 366 children were surveyed; 13 063 were eligible to 
receive four treatments, of whom 91·7% (89·3–94·2) 
were treated at least once. The mean coverage per month 
was 74·8% (72·2–77·3), and, as in 2015, just more than 
half of eligible children received four treatments (53·0% 
[48·5–57·4]). Coverage varied among countries and was 
consistently highest in Burkina Faso (table 1). Reported 
adherence to the 3 day regimen in the most recent 
month ranged from 86·8% (95% CI 81·7–90·7; Nigeria 
in 2016) to 99·8% (99·0–99·9; Burkina Faso in 2016). 
Delivery was equitable with similar levels of coverage 
Figure 2: Effectiveness of SMC
(A) Case-control estimates of the effectiveness of SMC treatments. Datapoints are the percentage reduction in 
malaria incidence in 28 days since the start of treatment, and 29–42 days post-treatment, compared with the 
incidence in children who had not received SMC within the last 42 days (underlying incidence data reported 
previously;21 appendix pp 6, 36). Error bars show 95% CIs (lower confidence limits of <20% were truncated at 
20% in the diagram, ending in a dashed line). The pooled estimates were obtained from a random effects meta-
analysis (appendix pp 11–12). For comparison, the efficacy during 28 days from randomised trials was 86%.10 
(B) The prevalence of molecular markers of resistance to sulfadoxine–pyrimethamine and amodiaquine in 2016 
and 2018 in individuals not eligible to receive SMC (aged 10–30 years). Error bars show 95% CIs. (C) Prevalence 
ratios with 95% CIs representing the fold increase in each marker from 2016 to 2018, in the 10–30 years age group 
(95% CIs for the pfdhfr, pfdhps-436Ala, and pfdhps-4367Gly variants were too narrow to display). Results in 
children younger than 5 years are given in the appendix (p 15). SMC=seasonal malaria chemoprevention. 
pfcrt=Plasmodium falciparum chloroquine resistance transporter. pfmdr1=P falciparum multidrug resistance 1. 
pfdhfr=P falciparum dihydrofolate reductase. pfdhps=P falciparum dihydropteroate synthetase. pfcrt-CVIET=amino 
acid positions 72–76.
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across wealth rankings in all countries in both years 
(appendix p 9). The surveys also showed that a high 
percentage of children aged 6–7 years received SMC 
(53·0% [95% CI 48·7–57·3] of children surveyed in 2015 
[n=1695] and 62·4% [55·7–69·1] in 2016 [n=2062] were 
treated at least once). In 2015, 87·4% (85·7–89·1) of 
children eligible for SMC slept under a long-lasting 
insecticide-treated net the night before the survey, and 
85·8% (83·3–88·2) did in 2016.
In our case-control studies, a total of 2185 cases with 
confirmed malaria, and 4370 controls, were enrolled 
during the 2015 (in The Gambia and Mali) and 2016 
(Burkina Faso, Chad, The Gambia, Mali, and Nigeria) 
transmission seasons. The pooled estimate of the 
protective effectiveness of SMC in reducing incidence 
of clinical malaria within 28 days of administration 
was 88·2% (95% CI 78·7–93·4; figure 2A). Effectiveness 
from 29 to 42 days post-treatment was 61·4% (47·4–71·8).
As of March 31, 2017, a total of 779 individual case 
safety reports related to SMC treat ment were available 
for 2015 and 2016, of which 36 were graded serious: 
one child with rash, two with fever, 31 with gastro-
intestinal disorders, one with extrapyramidal syndrome, 
and one with Quincke’s oedema. All children recovered 
from these serious adverse events. No cases of severe 
skin reactions (Stevens–Johnson syndrome or Lyell 
syn drome) were reported. A further serious adverse 
event was reported on Aug 16, 2017, a child who died 
due to suffocation from aspirating the SMC dissolved 
tablets after administra tion when not fully awake. In 
the cohort of children in Nigeria, the most commonly 
reported symptoms in 10 445 children seen after the 
first treat ment cycle were fever (549 [5·3%] children), 
vomiting (333 [3·2%]), and diarrhoea (233 [2·2%]). In 
6457 children seen after the third treatment cycle, again 
fever (178 [2·8%] children), vomiting (128 [2·0%]), and 
diarrhoea (70 [1·1%]) were the most common symptoms. 
In these children there were six spontaneous reports by 
facility staff of adverse drug-related reac tions after 
presentation at health facilities with suspected adverse 
effects. These were four cases of rash, one of oedema, 
and one of vomiting, each in a separate child. None of 
these events were classed as serious.
In our 2016 survey of drug resistance markers, 
29 274 samples from different individuals were analysed. 
14 345 samples were from children younger than 5 years 
and 14 929 were from individuals aged 10–30 years, of 
which 2844 and 2286, respectively, were positive for 
P falciparum and were resistance-typed. In 2018, 
28 546 samples were analysed; 14 019 samples were from 
Figure 3: Examples of the effect of SMC on malaria rates
(A) Numbers of confirmed cases of malaria in outpatient clinics, hospital inpatients admitted with a primary diagnosis of malaria, and deaths in hospital 
attributed to malaria, among children younger than 5 years and individuals aged 5 years and older, during transmission periods before and after SMC introduction 
for children younger than 5 years in the Upper River and Central River regions of The Gambia. (B) Numbers of confirmed cases of malaria among children younger 
than 5 years and individuals aged 5 years and older, in Kadiolo health centre, Sikasso region, Mali, each month before and after introduction of SMC for children 
younger than 5 years. SMC=seasonal malaria chemoprevention.
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children younger than 5 years and 14 527 were from 
individuals aged 10–30 years, with 801 and 1375, 
respectively, that were positive and resistance-typed.
In children younger than 5 years, the combination of 
the pfcrt-CVIET (amino acid positions 72–76), pfmdr1-
86Tyr, and pfmdr1-184Tyr variants, asso ciated with resis-
tance to amodiaquine, was found with a prevalence 
of 1·3% (95% CI 0·9–2·0) in 2016 and 0·5% (0·2–1·4) 
in 2018 (prevalence ratio 0·4 [0·1–1·1]). The prevalence of 
the quintuple mutation associated with resistance to 
sulfadoxine–pyrimethamine (triple mutation in pfdhfr 
with pfdhps-437Gly and pfdhps-540Glu) was 0·4% 
(0·2–0·8) in 2016 and 0·7% (0·3–1·5) in 2018 (prevalence 
ratio 1·8 [0·7–5·0). In the 10–30 age group, the corres-
ponding estimates for the combination of pfcrt-CVIET, 
pfmdr1-86Tyr and pfmdr1-184Tyr were 0·7% (0·4–1·2) 
in 2016 and 0·4% (0·1–0·8) in 2018 (prevalence ratio 0·5 
[0·2–1·2]), and for the quintuple mutation (triple muta-
tion in pfdhfr with pfdhps-437Gly and pfdhps-540Glu), 
0·2% (0·1–0·5) in 2016 and 1·0% (0·6–1·6) in 2018 
(prevalence ratio 4·8 [1·7–13·7]). The prevalence of each 
mutation in 2016 and 2018 for the 10–30 age group is 
shown in figure 2B. The three variants associated with 
resistance to amodiaquine decreased in prevalence 
between the surveys, while mutations in the pfdhfr gene, 
associated with resistance to pyrimethamine, and in the 
pfdhps gene, associated with resistance to sulfadoxine, 
each increased in prevalence. The fold-rise for each 
variant is shown in figure 2C. The pfdhps-540Glu 
mutation, which, combined with pfdhps-436Ala or pfdhps-
437Gly, confers resistance to sulfadoxine–pyrimethamine, 
was uncommon but its prevalence increased. Corres-
ponding results in children younger than 5 years are 
shown in the appendix (p 15).
In 2016, only two samples (one in each age group) 
carried the quintuple mutation and pfcrt-CVIET, pfmrd1–
86Tyr, and pfmdr1–184Tyr, the combination associated 
with resistance to sulfadoxine–pyrimethamine and 
amodiaquine (prevalence of 0·05% [0·01–0·18]). In 2018, 
no samples carried genotypes associated with resistance 
to both sulfadoxine–pyrimethamine and amodiaquine.
In The Gambia, SMC was introduced in the Upper 
River and Central River regions in 2014 (appendix p 2) 
and continued in the same areas via the ACCESS-SMC 
project in 2015 and 2016 (figure 1). Regarding the effect 
on malaria mortality, 155 malaria deaths were reported in 
hospitals (DHIS2 database) in children younger than 
5 years during the transmission seasons in the 3 years 
before introduction of SMC (2011–13), compared with 
18 deaths in the corresponding periods in the 3 years 
with SMC implementation (2014–16; figure 3). The overall 
reduction in malaria mortality associated with imple-
mentation of SMC (2014–16 vs 2011–13) estimated from 
Poisson regression was 56·6% (95% CI 28·9–73·5; 
table 2). In Burkina Faso, in areas where SMC was 
implemented from 2015, 612 malaria deaths were 
reported in district hospitals (DHIS2 database) in children 
younger than 5 years during the transmission seasons 
in the previous two years (2013–14), compared with 
336 deaths in 2015 and 2016 when SMC was implemented. 
In the districts that introduced SMC from 2016, the 
number of malaria deaths in children younger than 
5 years was 266 in 2013, 284 in 2014, and 281 in 2015, and 
76 in 2016. The estimated reduction in deaths associated 
with SMC was 42·4% (5·9–64·7; table 2). The number of 
severe malaria cases reported in children younger than 
5 years in the Upper River and Central River regions of 
The Gambia during the transmission season was 867 
in 2011, 619 in 2012, and 989 in 2013 (figure 3). Following 
introduction of SMC, the number decreased to 175 
in 2014, 233 in 2015, and 166 in 2016, representing a 
reduction of 54·8% (29·2–71·1; table 2). In Burkina Faso 
there was a 27·4% (20·5–33·7) reduction in 2015 (data 
for 2016 not available at time of analysis). Across all 
seven countries, estimated reductions in the number 
of confirmed outpatient malaria cases during the 
Source* 2015 2016 Overall
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The percentage reduction in the number of outpatient cases of malaria in children younger than 5 years at health 
facilities during the high transmission season, associated with the introduction of SMC, was estimated by fitting a 
Poisson regression model to the monthly number of confirmed cases treated at health facilities (appendix pp 25–29), 
with age group and calendar year as factors and the effect of SMC estimated with an indicator variable set to 1 for the 
age group during the months when SMC was implemented and set to 0 otherwise, with a robust standard error to 
calculate 95% CIs (appendix pp 19–24). Negative values indicate a relative increase. SMC=seasonal malaria 
chemoprevention. DHIS2=District Health Information System 2. *DHIS2 district-level data or data collected from 
selected outpatient clinics; 160 clinics were visited to inspect quality and completeness of data, and data were analysed 
from 73 clinics that had complete data on confirmed malaria cases for at least one year before and one year after SMC 
introduction. †For The Gambia, overall figures include data for 2014 (malaria deaths, 62·6% [16·9 to 83·2]; malaria 
inpatients, 61·5% [47·3 to 71·8]; malaria outpatients, 46·8% [42·0 to 51·2]). ‡Data on severe malaria not available 
for 2016 in the DHIS2 database at the time of data analysis. 
Table 2: Reductions in malaria in children younger than 5 years when SMC was introduced
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intervention periods (2015–16) ranged from 25·0% 
(5·4 to 40·5) in Nigeria in 2016 to 58·8% (43·0 to 70·3) 
in The Gambia in 2016 (table 2).
The total recurrent economic cost of SMC in 2016 
(for all ages) was US$22·8 million, comprising 
US$20·6 mil lion in financial costs and US$2·2 million 
in volunteer oppor tunity costs. The weighted average 
economic cost of administering four monthly SMC cycles 
to a single child across the seven countries was US$3·63, 
ranging from US$2·71 in Niger to US$8·20 in The 
Gambia. The estimate of the average total economic cost 
per malaria case averted, based on modelled estimates of 
the incidence of malaria in the absence of SMC (appendix 
p 34), ranged from US$2·91 in Niger to US$30·73 in 
The Gambia. The average total cost per severe malaria 
case averted ranged from US$119·63 in Niger to 
US$506·00 in The Gambia, and the average cost per 
death averted ranged from US$533·56 in Niger to 
US$2256·92 in The Gambia. Potential cost savings were 
estimated to be US$66·0 million in total, ranging from 
US$291 966 in The Gambia to US$20·1 million in 
Nigeria. The net economic cost savings (deducting the 
costs of administering SMC) were US$43·2 million 
across the seven countries.
Discussion
The ACCESS-SMC project sought to show the effec-
tiveness of SMC at scale and improve the market for 
SMC drugs, to overcome barriers to scale-up. Despite 
challenges of delivering SMC, almost 90% of children 
received at least one treatment, and more than 50% of 
children received all four treatments each year. Door-to-
door distribution was successful in reaching the poorest 
in the community. Although adherence to unsupervised 
doses is difficult to verify, caregiver-reported adherence 
was high. The protective effectiveness of each monthly 
treatment was similar to the efficacy observed in ran-
domised controlled trials.6,7 In two countries with DHIS-2 
databases established before SMC scale-up (The Gambia 
and Burkina Faso), estimated reductions of 57% and 
42% in the number of malaria deaths in district hospitals 
were determined for the SMC inter vention period, and 
reductions of 53% and 45% in the number of outpatient 
cases. Similar reductions were found in the number of 
outpatient malaria cases in other countries. These results 
represent the first large-scale evaluation of SMC imple-
mented by national pro grammes, and provide the first 
evidence of an impact on malaria deaths. Earlier studies 
in Burkina Faso and Mali showed effects on prevalence22,23 
and preliminary data on cost-effectiveness was obtained 
in Ghana.24
ACCESS-SMC substantially increased the demand 
for SMC drugs, accounting for about 50% of all 
SMC treatments procured in 2016 (unpublished data). 
In 2015, a sweetened, dispersible product was submitted 
to the WHO Prequalification of Medicines Programme 
and to the Global Fund Expert Review Panel for 
Pharmaceutical Products. Panel approval was obtained in 
February, 2016, allowing ACCESS-SMC to use dispersible 
tablets for most treatments admin istered in 2016 (WHO 
prequalification was obtained on Aug 21, 2018). By 2017, 
all SP+AQ orders for SMC were for the dispersible 
formulation. National malaria control programmes have 
been able to transition to other sources of funding to 
sustain SMC in all ACCESS-SMC areas and to expand 
delivery, supported primarily by the Global Fund, 
national governments, the President’s Malaria Initiative, 
UNICEF, and the World Bank. In addition, philanthropic 
funding supports Malaria Consortium programmes in 
Burkina Faso, Chad, and Nigeria.
Estimates of the effect on malaria rates could have 
been influenced by confounding, due to concurrent 
effects of other control measures, changes in access to 
health care, rates of parasitological testing of suspected 
malaria cases, and improvements in management of 
severe cases. However, as SMC is limited to children 
younger than 5 years, data could also be used from older 
age groups that did not receive SP + AQ, to at least partly 
control for temporal trends. Use of insecticide-treated 
bednets, which was assessed during SMC coverage sur-
veys, did not increase differentially in eligible children 
during the period of SMC scale-up. Malaria testing rates 
increased, but this increase was similar in all age groups 
(appendix p 12).
No cases of severe skin reactions were reported in this 
study, although cases have occurred after SMC.25 It is 
possible that serious cases occurred and were not reported. 
A limitation in assessing case reports has been the 
absence of biochemical and haematological parameters, 
which might have led to underdetection of liver injury and 
we were not able to monitor cases of agranulocytosis. An 
independent review of the safety of SMC by the WHO 
Advisory Committee on Safe of Medicines and Medicinal 
Products, based on data from this project and reports 
from other countries implementing SMC,25,26 endorsed 
the activities undertaken to promote safe administration 
of SMC and to strengthen safety monitoring, and con-
cluded that the risk–benefit profile of SMC is positive,27,28 
but noted that further strengthening of pharmacovili-
gance is needed to ensure prompt investigation of 
suspected cases and improve com pleteness of reports. 
Assessment of a causal link to SMC dugs was often 
problematic. Assessing causality from the information in 
Vigibase was not possible, due to incompleteness of 
information and difficulty in eliminating other causes of 
adverse effects such as dysentery and malaria. CHWs 
were trained to exclude children who were unwell from 
receiving SMC, but symptoms might not be apparent in 
the early stages of an illness, and therefore children who 
were unwell shortly after SMC due to a pre-existing illness 
might have been included.
SMC will reduce natural acquisition of immunity,29 
as is the case for effective malaria prevention by any 
method, but we have shown that SMC improves 
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survival in children. Children older than 5 years who 
stop receiving SMC are expected to be at increased risk of 
malaria compared with when they received SMC, and 
this risk should be monitored. Steps should be taken to 
ensure this age group use long-lasting insecticide-treated 
bednets and other preventive measures, and seek 
treatment promptly if they have fever.
Molecular markers of resistance to SMC drugs occurred 
at low prevalence, consistent with the effectiveness of 
SMC observed in the case-control studies. However, there 
was evidence of selection for resistance to sulfadoxine–
pyrimethamine in parasites sampled from the age group 
that did not receive SMC but lived in areas where SMC 
was deployed. The use of artemether–lumefantrine as a 
first-line therapy for malaria provides some protection 
against amodiaquine resistance, as it is effective against 
amodi aquine-resistant parasites, but it provides no corres-
ponding protection against sulfadoxine–pyrimethamine 
resis tance. Resistance to both sulfadoxine–pyrimethamine 
and amodiaquine should continue to be monitored via 
standardised methods, across all regions where SMC is 
used, to provide early warning of loss of effectiveness.
SMC is a relatively low-cost intervention, and con-
tributed to substantial cost savings for national health 
systems, by substantially reducing malaria burden and 
costs for malaria diagnosis and treatment. However, 
the level of SMC coverage varied. High levels of SMC 
coverage were possible with door-to-door delivery, 
but were not achieved everywhere. Important factors in 
maintaining high levels of coverage month-to-month 
include effective communication to inform communities 
about dates of campaigns, effective systems to ensure 
prompt payment of drug distributors, and adequate 
quantification to avoid stock-outs.
Supported by results from this project (referenced in 
the appendix [pp 6, 36]), the use of SMC has been rapidly 
expanded since 2016, with programmes in 13 countries 
(Benin, Burkina Faso, Cameroon, Chad, The Gambia, 
Ghana, Guinea, Guinea Bissau, Mali, Niger, Nigeria, 
Senegal, and Togo) reaching about 22 million children in 
2019 (appendix p 14; unpublished data). However, about 
8 million children live in areas identified as suitable for 
SMC that did not have SMC programmes in 2019, and 
this gap needs to be closed. As the use of SMC is 
expanded, monitoring coverage and adapting delivery 
approaches will be important, to ensure all children can 
be reached each month. Additionally, cycles should be 
strictly 28 days apart in view of the rapid drop in 
protection after this time. In view of the success with 
which SMC has been implemented in recent years, wider 
use could be considered,30 with addition of a fifth monthly 
cycle in regions with highly seasonal transmission but 
where the main risk period is longer than 4 months. 
Where justified by the disease burden, inclusion of older 
children should also be considered, as has been done 
successfully in Senegal.25 The ACCESS-SMC project 
drove demand for SMC drugs, which encouraged 
manufacturers to increase capacity and develop child-
friendly formulations. This evaluation showed that 
despite the challenges of delivering monthly treatments 
door to door, high coverage can be achieved, reducing 
morbidity and mortality caused by malaria. These results 
should support efforts to sustain and optimise the use of 
SMC to prevent malaria in children.
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